Cardiovascular disease risk after breast cancer treatment in patients with a BRCA1/2 pathogenic variant.
Terra L, Boekel NB, Hooning MH, Collee M, Schmidt MK, Adank MA, Kok M, Aleman BMP, Jager A, Sattler MGA, Maas AHEM, Schaapveld M, van Leeuwen FE.
Terra L, et al. Among authors: kok m.
Breast Cancer Res Treat. 2024 Oct 31. doi: 10.1007/s10549-024-07516-2. Online ahead of print.
Breast Cancer Res Treat. 2024.
PMID: 39482556